AIDSInfo logo
Home > Clinical Guidelines > Adult and Adolescent Guidelines

Adult and Adolescent Guidelines

Related Content
Order PublicationSupplementsSlide SetsManualsFact Sheets
DrugsHow to CiteClinical Trials 
DrugsBack
Adapted from Adult Treatment Guidelines Table 6: Antiretroviral Therapy for Treatment-Naive Patients (Updated November 3, 2008)

Patients naive to antiretroviral therapy should be started on a combination regimen that consists of either: 1 NNRTI + 2 NRTIs or 1 PI (preferably boosted with ritonavir) + 2 NRTIs 
  NNRTI Options Population in which to avoid or use with caution
Preferred  
  Efavirenz Do not use during 1st trimester of pregnancy or in those with high pregnancy potential  
      Use with caution in patients with unstable psychiatric disease  
         
  Alternative      
  Nevirapine   Do not use in patients with moderate to severe hepatic impairment (Child-Pugh score B or C)   
      Do not use in women with pre-ARV CD4 >250 or in men with pre-ARV CD4 >400  
      Use with caution in patients on tenofovir/emtricitabine (or lamivudine). Early virologic failure has been reported with this combination.   
PI Options Population in which to avoid or use with caution
  Preferred (alphabetical order)      
  Atazanavir + ritonavir (1x/day)   Do not use in patients who require high-dose (>20mg omeprazole equivalent/day) proton pump inhibitors (PPIs)  
  Darunavir +ritonavir (1x/day)      
  Fosamprenavir + ritonavir (2x/day)      
  Lopinavir/ritonavir (1x or 2x/day)   Do not use lopinavir/ritonavir in pregnant women   
  Alternative (alphabetical order)      
  Atazanavir (unboosted)(1x/day)   Do not use atazanavir in combination with tenofovir or didanosine/lamivudine  
  Fosamprenavir + ritonavir (1x/day) or fosamprenavir unboosted (2x/day)      
  Saquinavir + ritonavir (2x/day)      
         
  Dual-NRTI Options Population in which to avoid or use with caution
  Preferred      
  Emtricitabine/tenofovir   Do not use in combination with unboosted atazanavir  
      Use with caution:  
with nevirapine due to reports of early virologic failure
      in patients with underlying renal insufficiency  
  Alternative      
  Abacavir/lamivudine   Do not use in patients who test positive for HLAB*5701  
      Use with caution in the presence of the following:  
      HIV RNA >100,000 copies/mL - higher rate of virologic failure reported in ACTG 5205  
      High risk for cardiovascular disease  
  Didanosine + lamivudine (or emtricitabine)   Do not use in combination with unboosted atazanavir  
      Do not use in patients with a history of pancreatitis or peripheral neuropathy  
  Zidovudine/lamivudine   Do not use in combination with unboosted atazanavir  
      Do not use in patients with a history of pancreatitis or peripheral neuropathy  
      Use with caution in the presence of pretreatment anemia and/or neutropenia (may improve or worsen with zidovudine)  
         
         
CitationBack
How to Cite the Adult and Adolescent Guidelines:
Panel on Antiretroviral Guidelines for Adult and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. November 3, 2008; pp 1-139. Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed (insert date) [insert page number, table number, etc. if applicable]
Clinical TrialsBack
20 studies were listed in the last 30 days.            

Not yet recruitingA Pilot Study Of A Novel Treatment Regimen, Maraviroc + Ritonavir Boosted Atazanavir, In Treatment Naive HIV-Infected Patients
Condition: Human Immunodeficiency Virus-1
RecruitingSwitching Nevirapine IR Based Regimen to Nevirapine XR Based Regimen in HIV-1 Infected Patients
Condition: HIV Infections
Not yet recruitingEffectiveness of Immediate and Deferred Antiretroviral Treatment in HIV-Infected Adults
Condition: HIV Infections
Not yet recruitingCan Presumptive Anthelminthic Treatment Delay the Progression of HIV in ART-naïve Patients in Rural Africa?
Condition: HIV; Helminthiasis
Not yet recruitingA Phase 2B Multicenter, Randomized, Comparative Trial Of UK-453,061 Versus Etravirine In Combination With Darunavir/Ritonavir And A Nucleotide/Nucleoside Reverse Transcriptase Inhibitor For The Treatment Of Antiretroviral Experienced HIV-1 Infected Subjects With Evidence Of NNRTI Resistant HIV-1
Condition: HIV-1
Not yet recruitingChloroquine for Reducing Immune Activation in HIV- Infected Individuals
Condition: HIV Infections
RecruitingSafety of and Immune Response to a Prime-Boost Vaccine Regimen in HIV-Uninfected Vaccine-Naive Adults
Condition: HIV Infections
Not yet recruitingPharmacokinetics of Antiretroviral Agents in HIV-Infected Pregnant Women.
Condition: HIV Infection
Not yet recruitingEarly and Intermittent Antiretroviral Therapy in Naive HIV Infected Adults
Condition: HIV Infections
Not yet recruitingSafety and Effectiveness of Raltegravir and Darunavir/Ritonavir in Treatment-Naive HIV-Infected Adults
Condition: HIV Infections
Not yet recruitingTMC207-TiDP13-C110: Interaction Study With Lopinavir/Ritonavir in Healthy Volunteer
Condition: Tuberculosis; HIV
Not yet recruitingA Study Of Different Doses Of UK-453, 061 Plus Truvada Compared To Efavirenz Plus Truvada In Patients Who Have Not Been Previously Treated For HIV-1
Condition: HIV-1
Not yet recruitingVX-950-TiDP24-C134: Drug-Drug Interaction Trial Between Combination of Efavirenz and Tenofovir Disoproxil Fumarate and Different Dosages of Telaprevir on Healthy Volunteer
Condition: Hepatitis C; AIDS; HIV; HCV
Not yet recruitingPartner-Specific HIV Risk Reduction Intervention for Drug-Using Adolescents
Condition: Sexually Transmitted Diseases; Substance-Related Disorders
Not yet recruitingInteractions Between Antiretrovirals (ARVs) and Combined Oral Contraceptives (COCs)
Condition: HIV/AIDS
RecruitingAcupuncture/Moxibustion (Acu/Moxa) for Distal Symmetric Peripheral Neuropathy (DSP) in HIV
Condition: Peripheral Neuropathy; HIV; AIDS
RecruitingThe Use of a Distress Thermometer in a Pediatric Research Setting: An Exploratory, Pilot Study
Condition: Cancer; HIV Infections
Not yet recruitingEfficacy and Safety of 2 Raltegravir Doses in Naive HIV-1-Infected Patients Receiving Rifampin for Active Tuberculosis
Condition: HIV; Tuberculosis
Not yet recruitingRenal Function Assessment in HIV Patient
Condition: Chronic Kidney Disease in HIV Patients
Not yet recruitingTMC125-TiDP2-C188: A Phase I, Open-Label Trial to Investigate the Pharmacokinetic Effect of Multiple-Dose TMC125 on Buprenorphine and Norbuprenorphine Administered in HIV-Negative Patients on Stable Buprenorphine/Naloxone Maintenance Therapy.
Condition: Pharmacokinetics; HIV
 
Important Notice:
This document has been submitted for publication to CDC's Morbidity and Mortality Weekly Report (MMWR) and should be considered a final draft. It is being posted on AIDSinfo to expedite dissemination of important clinical information. Upon acceptance and publication in MMWR, this draft will be removed and replaced by the published version. In the meantime, readers should be aware that the content of the draft might differ from the content of future published versions. Any corrections/questions concerning this document should be addressed to Ms. Jessica Carrington (e-mail: contactus@aidsinfo.nih.gov).
 
Close window